J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Posted ContentDOI
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma
Neeraj Jain,Keenan Hartert,Saber Tadros,Warren Fiskus,Ondrej Havranek,Man-Chun John Ma,Alyssa Bouska,Tayla Heavican,Dhiraj Kumar,Qing Deng,Dalia Moore,Christine Pak,Liu C,Andrew J. Gentles,Elena Hartmann,Robert Kridel,Karin Ekstrom-Smedby,Gunnar Juliusson,Richard Rosenquist,Randy D. Gascoyne,Andreas Rosenwald,Fillippo Giancotti,Sattva S. Neelapu,Jason R. Westin,Julie M. Vose,Matthew A. Lunning,Timothy C. Greiner,Scott J. Rodig,Javeed Iqbal,Ash A. Alizadeh,Richard E. Davis,Kapil N. Bhalla,Michael R. Green +32 more
TL;DR: It is shown that TCF4 and IgM expression can be extinguished, and ABC-like DLBCL cells can be killed in vitro and in vivo, and provides a functional rationale for the use of BET inhibitors in this disease.
Journal ArticleDOI
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
Ranjana H. Advani,Alison J. Moskowitz,Nancy L. Bartlett,Julie M. Vose,Radhakrishnan Ramchandren,Tatyana Feldman,Ann S. LaCasce,Beth A. Christian,Stephen M. Ansell,Craig H. Moskowitz,Keenan Fenton,Carol Anne Ogden,David W. Taft,Daniel E. Zak,Mariana Sacchi,Faith Galderisi,Alex F. Herrera +16 more
TL;DR: Safety, efficacy, and biomarkers consistent with immune activation were observed in pts with R/R cHL and updated progression free survival (PFS) from Parts 1 & 2 are presented.
Journal ArticleDOI
Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
T. E. Witzig,Peter H. Wiernik,Timothy E. Moore,Craig B. Reeder,Craig E. Cole,Glen Justice,Henry G. Kaplan,M. Voralia,Dennis Pietronigro,Julie M. Vose +9 more
TL;DR: Oral lenalidomide monotherapy produces durable responses with manageable side effects in relapsed or refractory indolent NHL and warrants further investigation in the treatment of indolents NHL.
Journal Article
Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
TL;DR: It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma, which has the potential to generate immunologic memory, which could provide prolonged remission.
Journal ArticleDOI
To Surveil or Not to Surveil.
James O. Armitage,Julie M. Vose +1 more
TL;DR: It is suggested that the chances of relapse for a patient with diffuse large B-cell lymphoma being detected on any particular follow-up visit are approximately one in 40 to 50, and that patients who underwent routine surveillance imaging were more likely to be diagnosed with a low disease burden and have better overall survival in a retrospective analysis.